Vanguard’s VHT offers lower fees and higher yield than Invesco’s biotech-focused IBBQ, targeting broad healthcare exposure over concentrated risk.
Vanguard Health Care ETF (VHT) undercuts Invesco Nasdaq Biotechnology ETF (IBBQ) with a 0.09% expense ratio, nearly half the 0.19% fee of its rival. The fund also delivers a 1.6% trailing-12-month yield, double IBBQ’s 0.8% payout, appealing to cost-conscious investors seeking steady returns.
VHT tracks a diversified benchmark of 411 healthcare equities, including Eli Lilly (LLY) at 14.19% and Johnson & Johnson (JNJ) at 8.89%. Its passive strategy contrasts with IBBQ’s focus on volatile biotech firms, offering broader sector stability but lower growth potential.
Investors weighing the two must balance VHT’s lower costs and yield against IBBQ’s targeted exposure to high-risk, high-reward biotech innovation.